TH155663A - - Google Patents
Info
- Publication number
- TH155663A TH155663A TH1501001041A TH1501001041A TH155663A TH 155663 A TH155663 A TH 155663A TH 1501001041 A TH1501001041 A TH 1501001041A TH 1501001041 A TH1501001041 A TH 1501001041A TH 155663 A TH155663 A TH 155663A
- Authority
- TH
- Thailand
- Prior art keywords
- layer
- compound
- substance
- tebet
- irbesartan
- Prior art date
Links
- 239000010410 layer Substances 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000011780 sodium chloride Substances 0.000 claims abstract 6
- 239000000126 substance Substances 0.000 claims abstract 6
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract 5
- 239000001095 magnesium carbonate Substances 0.000 claims abstract 5
- 239000011776 magnesium carbonate Substances 0.000 claims abstract 5
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract 5
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims abstract 4
- YCPOHTHPUREGFM-UHFFFAOYSA-N Irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960002198 irbesartan Drugs 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 3
- 230000036912 Bioavailability Effects 0.000 claims abstract 2
- 208000009576 Hypercholesterolemia Diseases 0.000 claims abstract 2
- 206010020772 Hypertension Diseases 0.000 claims abstract 2
- 230000035514 bioavailability Effects 0.000 claims abstract 2
- 239000002131 composite material Substances 0.000 claims abstract 2
- 238000004090 dissolution Methods 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drugs Drugs 0.000 claims abstract 2
- 239000002355 dual-layer Substances 0.000 claims abstract 2
- 238000009472 formulation Methods 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 230000004526 pharmaceutical effect Effects 0.000 claims 1
Abstract
คำขอใหม่ปรับปรุง ที่เปิดเผยคือสูตรผสมเทเบล็ทเชิงประกอบแบบชั้นคู่ซึ่งประกอบรวมด้วย (a) ชั้นแรกซึ่ง ประกอบรวมด้วยอิร์เบซาร์แทนหรือเกลือที่ยอมรับได้เชิงเภสัชกรรมของสารนั้น; และ (b) ชั้นที่สอง ซึ่งประกอบรวมด้วยแอทอร์แวสแททินหรือเกลือที่ยอบรับได้เชิงเภสัชกรรมของสารนั้น และ แมกนีเซียมคาร์บอเนท (MgCO3 ) ในอัตราส่วนน้ำหนักเป็น 14 ถึง 1:5, และวิธีการสำหรับการเตรียม สิ่งเดียวกันนั้น ซึ่งแสตงอัตราเร็วการละลายและสภาพพร้อมให้ทางชีวภาพที่ดีเยี่ยม, สูตรผสมเทเบล็ท เชิงประกอบแบบชั้นคู่นั้นมีประโยชน์เป็นเชิงบำบัดสำหรับไฮเพอร์เทนชัน และไฮเพอร์คอเลสเทอโร ลีเมีย: สิทธิบัตรยา New requests, improvements The disclosed is a double-layer compound tebet blended formulation containing (a) the first layer, which is composed of irbesartan or the pharmacologically acceptable salt of the substance; And (b) the second layer, consisting of athervastatin or the pharmacologically treated salts of that substance and magnesium carbonate (MgCO3) in a weight ratio of 14 to 1: 5, And methods for their preparation Same thing Which shows excellent dissolution speed and bioavailability, the compound tebet Dual-layer composites are useful as a therapy for hypertension. And Hypercholesterolemia: Drug Patents
Claims (2)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH155663A true TH155663A (en) | 2016-09-06 |
| TH1501001041A TH1501001041A (en) | 2016-09-06 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690848A1 (en) | Derivatives of Bicyclic Pyridyl with Condensed Rings as FGFR4 Inhibitors | |
| EA201592256A1 (en) | DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES | |
| EA201592250A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseases | |
| EA201690223A1 (en) | FACTOR INHIBITORS IN THE COMPLEMENT BASED ON PIPERIDININILINDOL DERIVATIVES AND THEIR APPLICATION | |
| EA201491671A1 (en) | Heterocyclic Compounds | |
| EA201592255A1 (en) | DERIVATIVES OF PYRAZOLOPIRROLIDIN-4-IT AS A BET INHIBITOR AND THEIR APPLICATION IN THE TREATMENT OF THE DISEASE | |
| HRP20171648T1 (en) | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor | |
| CY1118662T1 (en) | NEW BICYCLE PYRIDINONS | |
| EA201690287A1 (en) | 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY | |
| EA201692298A1 (en) | DERIVATIVES OF CARBOXAMIDES | |
| JP2016515550A5 (en) | ||
| EA201691231A1 (en) | PHARMACEUTICAL MEDICINE FORMS | |
| EA201590474A1 (en) | PHARMACEUTICAL COMPOSITION BASED ON COMPOSITE CAPSULES INCLUDING IRBESARTAN AND HMG-COA REDUCTASE INHIBITOR | |
| EA201691058A1 (en) | DERIVATIVES OF PYRROLOPIRROLON AND THEIR APPLICATION FOR THE TREATMENT OF DISEASES | |
| EA201692090A1 (en) | POLYCYCLIC ACTIVATORS HERG | |
| TH155663A (en) | ||
| ECSP15010600A (en) | TWO-PHASE COMPOSITE TABLET FORMULATION INCLUDING ATORVASTATIN, IRBESARTAN AND MAGNESIUM CARBONATE | |
| HRP20171514T1 (en) | Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors | |
| HRP20201050T1 (en) | Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists | |
| RU2013127881A (en) | APPLICATION OF THE PHARMACEUTICAL COMPOSITION BASED ON THE SALT OF QUATERNARY PHOSPHONY AND SUBSTITUTED DINITROBENZOFUROXAN FOR THE TREATMENT OF Pyroplasmosis in Dogs and the Method of Treatment | |
| TH153211A (en) | Neprilisin inhibitor | |
| TR201005911A2 (en) | A drug formulation with improved dissolution profile. | |
| EA201301190A1 (en) | PHARMACEUTICAL COMPOSITION ERLOTINIBA | |
| TH162211A (en) | Compound 2-piridone | |
| TH134142A (en) | 2-Amino-3- (Imidazol-2-Il)-Piridin-4-Transfer Derivatives And its use as an inhibitor of VEGF receptor kinase |